肥胖是糖尿病、代谢综合征、癌症等疾病的独立危险因素,大量现代循证医学及分子生物学研究证明免疫炎症调控在肥胖防治中发挥关键作用,巨噬细胞极化失衡与T淋巴细胞亚群比例失调是导致肥胖-慢性炎症-胰岛素抵抗的重要病理机制。相关研究已证明中医药疗法可调控巨噬细胞极化与T淋巴细胞比例实现对肥胖的防治。因此,基于中医药循证研究证据,系统综述中医药靶向M1/M2巨噬细胞极化与T淋巴细胞亚群平衡改善肥胖的研究进展,以期为肥胖免疫稳态调控的中医药临床诊治及病理机制探索提供更高水平的证据支持。

Obesity is an independent risk factor for diabetes, metabolic syndrome, cancer and other diseases. A large number of modern evidence-based medical and molecular biological studies have proved that immune inflammatory regulation plays a key role in the prevention and treatment of obesity. The imbalance of macrophage polarization and the disorder of T lymphocyte subsets are important pathological mechanisms leading to obesity - chronic inflammation - insulin resistance. Relevant studies have proved that traditional Chinese medicine therapy can regulate macrophage polarization and T lymphocyte subsets to prevent and treat obesity. Therefore, based on the evidence of traditional Chinese medicine evidence-based research, this study systematically reviewed the research progress of traditional Chinese medicine targeting M1/M2 macrophage polarization and T lymphocyte subset balance to improve obesity, in order to provide higher-level evidence support for the clinical diagnosis and treatment and pathological mechanism exploration of obesity immune homeostasis regulation by traditional Chinese medicine.

国家科技四大慢病重大专项资助项目(项目编号:2023ZD0509400):代谢综合征心脑血管事件风险人群的双向队列构建及中医药一体化干预疗效评价,负责人:陈秋；成都中医药大学“杏林学者”学科人才科研提升计划(项目编号:MPRC2021006):基于“脾气散精”理论探究培土逐浊法调控肥胖记忆-CD4+T细胞抑制肥胖反弹的效应机制,负责人:周珊。